Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes / 肿瘤防治研究
Cancer Research on Prevention and Treatment
; (12): 409-413, 2021.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-988386
Biblioteca responsável:
WPRO
ABSTRACT
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development of precise medical treatment of MDS has been promoted. Small-molecule inhibitors, such as transforming growth factor β inhibiter, telomerase inhibiter and hypoxia-inducible factor prolyl hydroxylase inhibitor, provide novel therapeutic strategies for patients. This article reviews the treatment of transfusion-dependent lower-risk MDS patients and discusses the latest clinical research and development of novel targeted agents.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Cancer Research on Prevention and Treatment
Ano de publicação:
2021
Tipo de documento:
Artigo